<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CD72 is a broadly expressed B-lineage specific surface antigen </plain></SENT>
<SENT sid="1" pm="."><plain>We used J3-109(anti-CD72) monoclonal antibody to examine primary neoplastic cells from patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> for CD72 expression </plain></SENT>
<SENT sid="2" pm="."><plain>CD72 was present at high levels in 70 of 100 B-lineage <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo> (ALL), but it was not expressed on cells from 23 T-lineage ALL patients or 9 <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>We have prepared an anti-CD72 immunotoxin by conjugating J3-109 monoclonal antibody to the ribosome-inactivating protein, <z:mp ids='MP_0010998'>PAP</z:mp>.J3-109-<z:mp ids='MP_0010998'>PAP</z:mp> effectively killed &gt; 99.9% of clonogenic blasts from a CD72+ B-lineage ALL cell line </plain></SENT>
<SENT sid="4" pm="."><plain>We used a <z:mp ids='MP_0002536'>SCID</z:mp> mouse model of aggressive human <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre-B ALL</z:e> to evaluate the in vivo anti-leukemic efficacy of the J3-109-<z:mp ids='MP_0010998'>PAP</z:mp> immunotoxin </plain></SENT>
<SENT sid="5" pm="."><plain>An intravenous challenge with 1 x 10(6) NALM-6-UM-1(<z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre-B ALL</z:e>) cells caused 100% of <z:mp ids='MP_0002536'>SCID</z:mp> mice to die of disseminated <z:hpo ids='HP_0001909'>leukemia</z:hpo> within 41 days </plain></SENT>
<SENT sid="6" pm="."><plain>Importantly, a three-day treatment with non-toxic doses of J3-109-<z:mp ids='MP_0010998'>PAP</z:mp> significantly improved event-free survival of <z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="7" pm="."><plain>The Kaplan-Meier estimate (+/- standard error) of the probability of event-free survival at 2 months after inoculation of NALM-6-UM-1 cells was 40 +/- 16% for <z:mp ids='MP_0002536'>SCID</z:mp> mice treated with a total of 15 micrograms J3-109-<z:mp ids='MP_0010998'>PAP</z:mp> (median survival = 58 days) as compared to 0 +/- 0% for PBS treated mice (median survival = 34 days) </plain></SENT>
<SENT sid="8" pm="."><plain>At 6 months after the inoculation of NALM-6-UM-1 cells, 10 +/- 9% of the J3-109-<z:mp ids='MP_0010998'>PAP</z:mp> treated <z:mp ids='MP_0002536'>SCID</z:mp> mice were still alive with no evidence of <z:hpo ids='HP_0001909'>leukemia</z:hpo>.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>